Familial hypercholesterolemia due to ligand-defective apolipoprotein B100. First case report in a Mexican family

Archives of Medical Research

Volumn 34, Issue 1, 2003, Pages 70-75

  Robles Osorio, Ludivina ^a   Ordoñez, Ma Luisa ^a   Aguilar Salinas, Carlos A ^a   Aurón Gómez, Moisés ^a   Tusié Luna, Ma Teresa ^a   Gómez Pérez, Francisco J ^a   Rull Rodrigo, Juan A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Apolipoprotein B; Atherosclerosis; Cholesterol; Familial hypercholesterolemia; Mexico

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIGAND; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; HETEROZYGOTE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; ISCHEMIC HEART DISEASE; MALE; MEXICO; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREVALENCE; SEQUENCE ANALYSIS; SIBLING; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHILD; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MEXICO; MIDDLE AGED; PEDIGREE; POINT MUTATION;

EID: 0037279865     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(02)00452-6     Document Type: Article

References (29)

1. Kane J.P., Havel R.J. Disorders of the biogenesis and secretion of lipoproteins containing the B apoproteins. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular bases of inherited diseases. Vol. 3. 2001;McGraw-Hill, New York. 2717-2752.pp.
2. Hansen P.S. Familial defective apolipoprotein B-100. Review. Danish Med Bull. 45:1998;369-382.
3. Tybjaerg-Hansen A., Steffensen R., Meinertz H., Schnohr P., Nordestgaard B.G. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 338:1998;1577-1584.
4. Teng Y.N., Pan J.P., Chou S.C.H., Tai D.Y., Lee-Chen G.J. Familial defective apolipoprotein B-100. detection and haplotype analysis of the Arg3500Gln mutation in hyperlipidemic Chinese Atherosclerosis. 152:2000;385-390.
5. Miserez A.R., Muller P.Y. Familial defective apoB100. a mutation emerged in the mesolithic period (letter) Atherosclerosis. 158:2001;253-254.
6. Garcés C., Rodríguez F., Serrano A., González J., Almagro F., Garrido J.A. Manifestaciones clínicas de la hipercolesterolemia familiar heterozigota en España. Estudio de 301 casos de la zona centro y norte. Med Clin (Barc). 22:2000;50-51.
7. Horvath A., Ganev V. The mutation APOB-100 R3500Q in Eastern Europe. Atherosclerosis. 156:2001;243-244.
8. Pullinger C.R., Gaffney D., Gutiérrez M.M., Mallory M.J., Schumaker V.N. The apolipoprotein B 3531 mutation. characteristics of 24 subjects from 9 kindreds J Lipid Res. 40:1999;318-327.
9. Fisher E., Schanrnagl H., Hoffmann M.M., Kusterer K., Wittmann D., Wieland H., Gross W., Marz W. Mutations in the apolipoprotein (apo) B-100 receptor-binding region. detection of apo B-100 (Arg3500Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405Gln) diminishes receptor-mediated uptake of LDL Clin Chem. 45:1999;1026-1037.
10. Yan Tai D., Pin Pan J., Jen Lee-Chen G. Identification and haplotype analysis of apolipoprotein B-100 Arg3500Trp mutation in hyperlipidemic Chinese. Clin Chem. 44:1998;1659-1665.
11. Miserez A.R., Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;1719-1729.
12. 3500-Gln) allele specific polymerase chain reaction. large-scale screening of pooled blood samples J Lipid Res. 33:1992;1563-1567.
13. Kalina A., Czeizel E., Romics L., Pados G., Reiber I., Dosa A., Hermany I., Lakatos Z., Tarjan J., Kollega-Tarsoly E., Kovaks M., Szalai C., Csaszar A. Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened for familial hypercholesterolemia in Hungary. Atherosclerosis. 154:2001;247-251.
14. Pullinger C.R., Hennessy L.K., Chatterton J.E., Liu W., Love J.A., Mundel C.M., Frost P.H., Malloy M.J., Schumaker V.N., Kane J.P. Familial ligand-defective apolipoprotein B. J Clin Invest. 95:1995;1225-1234.
15. Mamotte C.D., van Bockxmeer F.M. A robust strategy for screening and confirmation of familial defective apolipoprotein B-100. Clin Chem. 39(1):1993;118-121.
16. Real J.T., Chaves F.J., Ejarque M.J., Catalá M.J., Priego M.A., Ascaso J.F., Armengod M.E., Carmena R. Familial defective apoB100 in a South European population. Atherosclerosis. 2:2001;69-70.
17. Miserez A.R., Muller P.Y. Familial defective apolipoprotein B-100. a mutation emerged in the Mesolithic ancestors of Celtic peoples? Atherosclerosis. 148:2000;433-436.
18. Innerarity T.L., Weisgraber K.H., Arnold K.S., Mahley R.W., Krauss R.M., Vega G.L., Grundy S.M. Familial defective apolipoprotein B-100. low density lipoprotein with abnormal receptor binding Proc Natl Acad Sci USA. 84:1987;6919-6923.
19. Ludwig E.H., McCarthy B.J. Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B100. Am J Hum Genet. 47:1990;712-720.
20. Accessible at: www.ucl.ac.uk/fh. Reviewed on August 13, 2002.
21. Scientific Steering Committee on behalf of the Simon Broome Register Group Mortality in treated heterozygous familial hypercholesterolemia. implications for clinical management Atherosclerosis. 142:1999;105-112.
22. Salazar L.A., Hirata M.H., Cavalli S.A., Nakandakare E.R., Forti N., Diament J., Giannini S., Bertolami M., Hirata R. Molecular basis of familial hypercholesterolemia in Brazil. identification of seven novel LDLR gene mutations Hum Mutat. 19:2002;462-463.
23. Alberto F.L., Figuerido M.S., Zago M.A., Araújo A.G., Santos J.E. The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil. Braz J Med Biol Res. 32:1999;739-745.
24. Williams R.R., Hunt S.C., Schumacher M.C., Hegele R.A., Leppert M.F., Ludwig E.H., Hopkins P.N. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 72:1993;171-176.
25. Schuster H., Luft F.C. Clinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 18:1998;331-332.
26. Hansen P.S., Defesche J.C., Kastelein J.J.P., Gerdes L.V., Fraza Z., Gerdes C. Phenotypic variation in patients heterozygous for familial defective Apo B in three European countries. Arterioscler Thromb Vasc Biol. 17:1997;741-747.
27. Boren J., Lee I., Zhu W., Arnold K., Taylor S., Innerarity T. Identification of the low density lipoprotein receptor binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apoB100. J Clin Invest. 101:1998;1084-1093.
28. März W., Baumstark M.W., Scharnagl H., Ruzicka V., Buxbaum S., Herwig J., Pohl T., Russ A., Schaaf L., Berg A., Böhles H.J., Usadel K.H., Gross W. Accumulation of small dense low density lipoproteins (LDL) in a homozygous patient with familial defective apolipoprotein B-100 results. J Clin Invest. 92:1993;2922-2933.
29. Aguilar-Salinas C.A. Hipercolesterolemia familiar. Rev Invest Clin. 53:2001;254-265.